1 Table of Contents 1 Table of Contents 2 2 Introduction 3 2.1 Report Guidance 3 3 Marketed Products 4 3.1 Overview 4 3.2 Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs 4 3.3 Anti-Tumor Necrosis Factor Alpha Biologic Disease Modifying Anti-Rheumatic Drugs, with or without Concomitant Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs 5 3.4 Non Anti-Tumor Necrosis Factor Alpha (TNFα) Biologic Disease Modifying Anti-Rheumatic Drugs, with or without Concomitant Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs 6 3.5 Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs with or without Concomitant Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs 7 4 Pipeline Products 9 4.1 Changes to Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs, 2015-2022 9 4.2 Changes to Anti-Tumor Necrosis Factor Alpha Biologic Disease Modifying Anti-Rheumatic Drugs, with or without Concomitant Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs, 2015-2022 9 4.3 Changes to Non-Anti-Tumor Necrosis Factor Alpha Biologic Disease Modifying Anti-Rheumatic Drugs, with or without Concomitant Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs, 2015-2022 9 4.4 Changes to Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs with or without Concomitant Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs, 2015-2022 10 5 Appendix 11 5.1 Abbreviations 11 5.2 References 12 5.3 Research Methodology 14 5.4 Contact Us 15 5.5 Disclaimer 15